Forecast: HIV-AIDS Mortality in the UK 2023 - 2027 Discover more data with ReportLinker!

The number of new cases of HIV diagnosed in the UK fluctuated over the observed period. In 2023, there were ***** new HIV cases recorded in the UK, highest in the given period. Cases of AIDS in the UK were significantly lower, with *** cases in 2023. STIs in the UK Other common STIs in the UK are herpes, gonorrhea, and chlamydia. Especially for gonorrhea and chlamydia, an increase in cases was observed between 2012 and 2019, while in 2020 and 2021 figures fell dramatically due to the COVID-19 pandemic and resulting lockdowns and social distancing. HIV in Europe New cases of HIV in Europe amounted to roughly **** thousand in 2023, of which **** thousand were among males. Among male individuals, the most common mode of HIV transmission in Europe in 2023 was among men having homosexual intercourse.

People aged 15 to 59 years seen at HIV services in the UK, expressed as a rate per 1,000 population.Data is presented by area of residence, and exclude people diagnosed with HIV in England who are resident in Wales, Scotland, Northern Ireland or abroad.RationaleThe geographical distribution of people seen for HIV care and treatment is not uniform across or within regions in England. Knowledge of local diagnosed HIV prevalence and identification of local risk groups can be used to help direct resources for HIV prevention and treatment.In 2008, http://www.bhiva.org/HIV-testing-guidelines.aspx recommended that Local Authority and NHS bodies consider implementing routine HIV testing for all general medical admissions as well as new registrants in primary care where the diagnosed HIV prevalence exceeds 2 in 1,000 population aged 15 to 59 years.In 2017, guidelines were updated by https://www.nice.org.uk/guidance/NG60 which is co-badged with Public Health England. This guidance continues to define high HIV prevalence local authorities as those with a diagnosed HIV prevalence of between 2 and 5 per 1,000 and extremely high prevalence local authorities as those with a diagnosed HIV prevalence of 5 or more per 1,000 people aged 15 to 59 years.When this is applied to national late HIV diagnosis data, it shows that two-thirds of late HIV diagnoses occur in high-prevalence and extremely-high-prevalence local authorities. This means that if this recommendation is successfully applied in high and extremely-high-prevalence areas, it could potentially affect two-thirds of late diagnoses nationally.Local authorities should find out their diagnosed prevalence published in UKHSA's http://fingertips.phe.org.uk/profile/sexualhealth , as well as that of surrounding areas and adapt their strategy for HIV testing using the national guidelines.Commissioners can use these data to plan and ensure access to comprehensive and specialist local HIV care and treatment for HIV diagnosed individuals according to the http://www.medfash.org.uk/uploads/files/p17abl6hvc4p71ovpkr81ugsh60v.pdf and http://www.bhiva.org/monitoring-guidelines.aspx .Definition of numeratorThe number of people (aged 15 to 59 years) living with a diagnosed HIV infection and accessing HIV care at an NHS service in the UK and who are resident in England.Definition of denominatorResident population aged 15 to 59.The denominators for 2011 to 2023 are taken from the respective 2011 to 2023 Office for National Statistics (ONS) revised population estimates from the 2021 Census.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsData is presented by geographical area of residence. Where data on residence were unavailable, residence have been assigned to the local health area of care.Every effort is made to ensure accuracy and completeness of the data, including web-based reporting with integrated checks on data quality. The overall data quality is high as the dataset is used for commissioning purposes and for the national allocation of funding. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is as reported but rely on ‘record linkage’ to integrate data and ‘de-duplication’ to prevent double counting of the same individual. The data may not be representative in areas where residence information is not known for a significant proportion of people accessing HIV care.Data supplied for previous years are updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may therefore differ from previous publications.Values are benchmarked against set thresholds and categorised into the following groups: <2 (low), 2 to 5 (high) and≥5 (extremely high). These have been determined by developments in national testing guidelines.The data reported in 2020 and 2021 is impacted by the reconfiguration of sexual health services during the national response to COVID-19.

The number of new cases of AIDS diagnosed in the UK generally decreased over the period observed to *** cases in 2023. This statistic displays the number of new cases of AIDS diagnosed in the United Kingdom from 2013 to 2023.

United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 10.900 % in 2016. This records a decrease from the previous number of 11.200 % for 2015. United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 12.200 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 16.400 % in 2000 and a record low of 10.900 % in 2016. United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s UK – Table UK.World Bank: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted Average;

Forecast: Number of Deaths Due to Tuberculosis (Excluding HIV Cases) in the UK 2022 - 2026 Discover more data with ReportLinker!

Women's share of population ages 15+ living with HIV (%) in United Kingdom was reported at 32.44 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. United Kingdom - Female adults with HIV (% of population ages 15+ with HIV) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

Forecast: Number of Deaths Due to Tuberculosis (Excluding HIV Cases) in the UK 2023 - 2027 Discover more data with ReportLinker!

Reports of Human immunodeficiency virus (HIV) diagnoses, diseases and deaths in HIV-infected persons

United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 12.900 NA in 2016. This records a decrease from the previous number of 13.300 NA for 2015. United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 14.600 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 20.000 NA in 2000 and a record low of 12.900 NA in 2016. United Kingdom UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 9.000 NA in 2016. This records a decrease from the previous number of 9.200 NA for 2015. UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 9.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 12.900 NA in 2000 and a record low of 9.000 NA in 2016. UK: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Kingdom – Table UK.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Abstract

Despite many gains earned by the provision of ART a good proportion of HIV infected patients still die within three months of initiation of ART. The reasons for this are not clear but include: continued risk of serious co-infection prior to recovery of immunity; intensification and detrimental inflammation with immune reconstitution (IRIS: immune reconstitution inflammatory syndrome); drug reactions; and/or ART started beyond the point of the bodies ability to recover. The clinical progression of HIV-infection is dominated by a relatively small number of frequent clinical syndromes resulting from opportunistic infections with specific aetiological agents. In Africa the commonest opportunistic infections are: Mycobacterium tuberculosis, Streptococcus pneumoniae, Cryptococcus neoformans, non-typhoidal Salmonella, human herpes virus 8, and Plasmodium falciparum. Many of these co-infections are preventable. How much each of these specific pathogens contributes to this early death and whether specific prophylaxis should be put in place is not clear. Careful clinical description backed up by quality controlled diagnostic services will help to define the role of these co-infections during the early phase of ART One successfully established on ART, failure will occur when ART resistance develops. This is not inevitable but the factors that lead to resistance are incompletely understood. Long term follow-up of individuals with careful assessment of drug adherence, co-infections, viral resistance and other clinical parameters will help to define targets for interventions to prolong the effective life of first line and subsequent ART. This study aimed to establish a cohort of HIV positive individuals eligible for ART and follow them with detailed clinical assessments and laboratory work in order to understand the determinants of death, co-infections (clinical failure) and virological failure while on ART in a rural Malawian population. Patients at ART clinics in the DSS area and Karonga district hospital (and later patients at pre-ART clinic before universal test and treat was implemented) were interviewed to gather information and link their clinic ID to their DSS ID. Clinic data were gathered from paper registers through digital photos of the register or from electronic records. NHSRC approval number: 448 Funded by Wellcome Trust 079828/Z/06/Z and 096249/Z/11/A

Analysis unit

Individual

Universe

· Age >15 years · HIV-infected · Resident within the demographic surveillance area of KPS

Mode of data collection

Face-to-face [f2f]

Research instrument

ARTI - ART Identification form - English HCCI - HCC Identification form - English

Broadly neutralising antibodies (bNAbs) targeting HIV show promise for both prevention of infection and treatment. Among these, 10-1074 has shown potential in neutralising a wide range of HIV strains. However, resistant viruses may limit the clinical efficacy of 10-1074. The prevalence of both de novo and emergent 10-1074 resistance will determine its use at a population level both to protect against HIV transmission and as an option for treatment. To help understand this further, we report the prevalence of pre-existing mutations associated with 10-1074 resistance in a bNAb-naive population of 157 individuals presenting to UK HIV centres with primary HIV infection, predominantly B clade, receiving antiretroviral treatment. Single genome analysis of HIV proviral envelope sequences showed that 29% of participants’ viruses tested had at least one sequence with 10-1074 resistance-associated mutations. Mutations interfering with the glycan binding site at HIV Env position 332 accounted for 95% of all observed mutations. Subsequent analysis of a larger historic dataset of 2425 B-clade envelope sequences sampled from 1983 to 2019 revealed an increase of these mutations within the population over time. Clinical studies have shown that the presence of pre-existing bNAb mutations may predict diminished therapeutic effectiveness of 10-1074. Therefore, we emphasise the importance of screening for these mutations before initiating 10-1074 therapy, and to consider the implications of pre-existing resistance when designing prevention strategies.

Introduction: The effect of HCV infection on HIV disease progression remains unclear; the effect of HCV infection duration on HIV disease progression is unknown. Methods: We used data from a cohort of HIV seroconverters to investigate the effect of HCV infection duration on time from HIV seroconversion to CD4 <350cells/mm3, AIDS or death, censoring at the earlier of cART initiation or last clinic visit, adjusting for confounders and splitting data into follow up periods from HIV seroconversion (<2, 2–4 and >4 years). We additionally compared CD4 cell decline following HCV infection to that of mono-infected individuals with similar HIV infection duration by fitting a random effects model. In a separate analysis, we used linear mixed models to we examine the effect of HCV infection and its duration on CD4 increase over 48 weeks following cART. Results: Of 1655 individuals, 97 (5.9%) were HCV co-infected. HCV<1 year was associated with a higher risk of endpoint in each follow-u...

United Kingdom UK: Maternal Mortality Ratio: Modeled Estimate: per 100,000 Live Births data was reported at 9.000 Ratio in 2015. This stayed constant from the previous number of 9.000 Ratio for 2014. United Kingdom UK: Maternal Mortality Ratio: Modeled Estimate: per 100,000 Live Births data is updated yearly, averaging 11.000 Ratio from Dec 1990 (Median) to 2015, with 26 observations. The data reached an all-time high of 12.000 Ratio in 2005 and a record low of 9.000 Ratio in 2015. United Kingdom UK: Maternal Mortality Ratio: Modeled Estimate: per 100,000 Live Births data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s UK – Table UK.World Bank: Health Statistics. Maternal mortality ratio is the number of women who die from pregnancy-related causes while pregnant or within 42 days of pregnancy termination per 100,000 live births. The data are estimated with a regression model using information on the proportion of maternal deaths among non-AIDS deaths in women ages 15-49, fertility, birth attendants, and GDP.; ; WHO, UNICEF, UNFPA, World Bank Group, and the United Nations Population Division. Trends in Maternal Mortality: 1990 to 2015. Geneva, World Health Organization, 2015; Weighted average; This indicator represents the risk associated with each pregnancy and is also a Sustainable Development Goal Indicator for monitoring maternal health.

The heterosexual risk group has become the largest HIV infected group in the United Kingdom during the last 10 years, but little is known of the network structure and dynamics of viral transmission in this group. The overwhelming majority of UK heterosexual infections are of non-B HIV subtypes, indicating viruses originating among immigrants from sub-Saharan Africa. The high rate of HIV evolution, combined with the availability of a very high density sample of viral sequences from routine clinical care has allowed the phylodynamics of the epidemic to be investigated for the first time. Sequences of the viral protease and partial reverse transcriptase coding regions from 11,071 patients infected with HIV of non-B subtypes were studied. Of these, 2774 were closely linked to at least one other sequence by nucleotide distance. Including the closest sequences from the global HIV database identified 296 individuals that were in UK-based groups of 3 or more individuals. There were a total of 8 UK-based clusters of 10 or more, comprising 143/2774 (5%) individuals, much lower than the figure of 25% obtained earlier for men who have sex with men (MSM). Sample dates were incorporated into relaxed clock phylogenetic analyses to estimate the dates of internal nodes. From the resulting time-resolved phylogenies, the internode lengths, used as estimates of maximum transmission intervals, had a median of 27 months overall, over twice as long as obtained for MSM (14 months), with only 2% of transmissions occurring in the first 6 months after infection. This phylodynamic analysis of non-B subtype HIV sequences representing over 40% of the estimated UK HIV-infected heterosexual population has revealed heterosexual HIV transmission in the UK is clustered, but on average in smaller groups and is transmitted with slower dynamics than among MSM. More effective intervention to restrict the epidemic may therefore be feasible, given effective diagnosis programmes.

BackgroundTo examine the effect of Sexual Health in Practice (SHIP) training for general practitioners (GPs) on HIV testing rates in Haringey, a deprived area of London, UK, with a population of over 250,000 and HIV prevalence of 0.7% (in 2014). SHIP is an educational intervention delivering peer-developed and peer-led face-to-face training to improve quality of sexual and reproductive health (SRH) care.MethodsWe carried out a quasi-experimental study of intervention effects across 52 GP practices (2008–2016). We used time variation in SHIP intervention exposure for effect estimation, controlling for practice and calendar month fixed effects in panel analysis. From 2008–2010, baseline data were collected, and in the subsequent six-year period, 78 GPs in Haringey (approximately 40% of all GPs) were SHIP trained. 46 Haringey practices (of 52) had at least one trained doctor. Outcome measures were monthly HIV tests and results by practice (obtained from the hospital laboratories).ResultsSHIP significantly increased HIV testing; for every GP trained, practice HIV testing rates increased by 16% (testing rate ratio (TRR) 1.16, 95% confidence interval (CI) 1.05–1.28, p value 0.004). This significant effect was demonstrated using an 8-year observation period, and was sustained over the post-intervention period. An average of 1.42% of HIV tests were positive.ConclusionSHIP training produces a significant and sustained increase in HIV testing for each GP trained. Compared with general population screening, HIV tests used in routine clinical care have a high probability of detecting a positive person. Unlike an RCT, this evaluation is a ‘real life’ measure of the effect that commissioners of SHIP could expect in comparable areas of the UK. The effectiveness of the SHIP training may be related to the programme components not included in interventions that did not demonstrate an effect, such as peer-led teaching, and use of approaches to communication and rapid risk assessment tailored to the setting.

All new STI diagnoses among people accessing sexual health services* in England. Data represent STI diagnoses among people who are resident in England. Data is presented by area of patient residence and include those residents in England and those with an unknown residence (data for those residents outside of England is not included). Data is expressed as a rate per 100,000 population.*Sexual health services providing STI related care (Levels 1, 2 or 3). Further details on the levels of sexual healthcare provision are provided in the Standards for the Management of STIs.

Rationale A summary figure of all new STI diagnoses.

Definition of numerator The number of new STI diagnoses among people accessing sexual health services in England who are also residents in England.STI data excluding chlamydia is sourced from the GUMCAD STI Surveillance System (Levels 2 and 3). GUMCAD data is reported by SHSs providing STI related care (Levels 2 or 3). Chlamydia data is sourced from GUMCAD (Level 3) and CTAD Chlamydia Surveillance System (Levels 1 and 2), UKHSA. CTAD data is reported by laboratories conducting testing for any service (Levels 1, 2 or 3) providing chlamydia testing.The Episode Activity codes (SNOMED or Sexual Health and HIV Activity Property Types (SHHAPT)) relating to diagnosis of: chancroid, Lymphogranuloma venereum (LGV), donovanosis, chlamydia, gonorrhoea, first episode anogenital herpes, new HIV diagnosis, molluscum contagiosum, non-specific genital infection (NSGI), pelvic inflammatory disease (PID) and epididymitis: non-specific, scabies and pediculosis pubis, syphilis (primary, secondary and early latent), trichomoniasis, first episode genital warts were used.In 2015, the new STI diagnoses group was expanded to include new codes that were not previously reported via GUMCADv2. The new codes include: Mycoplasma genitalium (C16); Shigella: flexneri, sonnei and unspecified (SG1, SG2, SG3).The clinical criteria used to diagnose the conditions are given at https://www.bashh.org/guidelines .Data was de-duplicated to ensure that a patient received a diagnostic code only once for each episode. Patients cannot be tracked between services and therefore de-duplication relies on patient consultations at a single service.

Definition of denominator The denominators for 2012 to 2022 are sourced from Office for National Statistics (ONS) population estimates based on the 2021 Census.Population estimates for 2023 were not available at the time of publication – therefore rates for 2023 are calculated using estimates from 2022 as a proxy.Further details on the ONS census are available from the https://www.ons.gov.uk/census .Caveats Every effort is made to ensure accuracy and completeness of GUMCAD data, including web-based reporting with integrated checks on data quality. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may differ from previous publications.Figures reported in 2020 and 2021 are notably lower than previous years due to the disruption to SHSs during the national response to the COVID-19 pandemic.